HanchorBio Invited to Present at the 9th BPD Biopharmaceutical Process Development Conference on Next-Generation Drug Manufacturing and CMC Development
Executive Director of CMC Vivian Kuo to join industry experts from Sanofi, Henlius, Hengrui Pharma and other leading companies, highlighting HanchorBio’s integrated capabilities spanning innovative molecule design, process development and clinical supply
[Taipei, Shanghai, San Francisco | August 5, 2026] – HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that Vivian Kuo, PhD, Executive Director of CMC, has been invited to speak at the 2026 9th BPD Biopharmaceutical Process Development Conference.
Dr. Kuo will deliver a presentation entitled “From Complexity to Control: Process and CMC Excellence for Next-Generation Innovative Therapeutics,” sharing HanchorBio’s practical experience in establishing developable, scalable and transferable process and chemistry, manufacturing and controls (CMC) capabilities for increasingly complex next-generation biologics. The conference will be held from August 6 to 7, 2026, at the Zhangjiang Science Hall in Shanghai.
The BPD Biopharmaceutical Process Development Conference focuses on the full development pathway from process development through commercial manufacturing, covering antibodies, fusion proteins, cell and gene therapies, quality management and intelligent manufacturing. As innovative biologic molecules become increasingly complex, process and CMC development must integrate molecular characteristics, product quality, manufacturing scale-up and regulatory requirements at an earlier stage, providing an essential foundation for advancing innovative therapies through clinical development and realizing their full product potential.
HanchorBio’s proprietary FBDB™ (Fc-Based Designer Biologics) platform is designed to generate multifunctional innovative fusion proteins. To address the complexity of these molecules in expression, purification, analytical characterization and quality control, the Company integrates molecular design, cell-line and process development, analytical methods, quality management and clinical supply. This approach enables the CMC team to participate in product strategy from the early stages of research and development, helping reduce uncertainty during scale-up, technology transfer and clinical development.
HCB101 provides one example of HanchorBio’s process-development capabilities. Through process optimization, the Company increased protein titer from an initial 0.8 g/L to 4.6 g/L, with further improvement reaching 6.5–7 g/L. The overall process recovery rate reached 80.7%, while product purity exceeded 99%, demonstrating HanchorBio’s capabilities in improving productivity, recovery efficiency and quality control.
Dr. Kuo’s presentation will examine development trends in next-generation therapeutic platforms and the process and CMC challenges associated with novel molecular formats. She will also discuss how HanchorBio applies cross-functional collaboration, process understanding and risk management to convert complex molecules into controlled and reproducible manufacturing processes. In addition, the presentation will explore how artificial intelligence and data analytics can deepen drug and process understanding and improve development decision-making.
Presentation Details
- Date: August 6, 2026
- Time: 3:20–3:40 p.m.
- Venue: Hall 3, Zhangjiang Science Hall, Shanghai
- Session: Process Development and Validation — Downstream Process Development for Novel Antibodies
- Presentation: “From Complexity to Control: Process and CMC Excellence for Next-Generation Innovative Therapeutics”
- Speaker: Vivian Kuo, PhD, Executive Director of CMC, HanchorBio
HanchorBio’s invitation to participate in the BPD conference reflects the practical experience the Company has accumulated in the process development of complex fusion proteins and next-generation biologics. Through in-depth exchanges with industry experts and upstream and downstream partners, HanchorBio aims to further strengthen its integrated capabilities from innovative molecule design and process development through clinical translation, while expanding opportunities for technology collaboration, co-development, process partnerships and global supply-chain cooperation.
HanchorBio believes that differentiated innovative molecules must be supported by robust CMC capabilities to advance clinical development effectively and support future product commercialization. The Company will continue to focus on product quality, process control and global development requirements while strengthening its CMC platform and cross-regional collaboration capabilities to provide more comprehensive development support for both its internal pipeline and potential partnership programs.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. Company’s proprietary Fc-based designer biologics (FBDB™) platform enables the engineering of multi-functional biologics with diverse targeting modalities, designed to activate both innate and adaptive immune pathways and address limitations of current immunotherapies.
HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations, translational development strategies, and scalable CMC capabilities.
Forward-Looking Statements
This press release contains forward-looking statements regarding HanchorBio’s research collaborations, development programs, product candidates, regulatory strategy, and future plans. Actual results may differ materially from those expressed or implied due to various risks and uncertainties, including clinical development outcomes, regulatory interactions, regulatory decisions, protocol development, and market conditions. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.